Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famotidine/ibuprofen - Horizon Therapeutics plc

Drug Profile

Famotidine/ibuprofen - Horizon Therapeutics plc

Alternative Names: Duexa; Duexis; HZT-501; Ibuprofen/famotidine

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Horizon Therapeutics
  • Developer Horizon Pharma; Horizon Pharma USA; Horizon Therapeutics plc
  • Class Antiulcers; Gastric antisecretories; Nonsteroidal anti-inflammatories; Phenylpropionates; Thiazoles
  • Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Discontinued Ankylosing spondylitis

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 27 Mar 2015 Famotidine/ibuprofen is still registered for prevention of Ankylosing spondylitis, NSAID-induced ulcer, Osteoarthritis and Rheumatoid arthritis in United Kingdom
  • 07 Mar 2013 Registered for Ankylosing spondylitis in United Kingdom (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top